The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease

  title={The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease},
  author={Loris Riccardo Lopetuso and Marco Napoli and Gianenrico Rizzatti and Antonio Gasbarrini},
  journal={Expert Opinion on Investigational Drugs},
  pages={543 - 551}
ABSTRACT Introduction: The gastrointestinal tract acts as a functional unit organized as a semipermeable multilayer system, in which commensal gut microbiota represents the anatomical barrier. Recently, several studies have highlighted the involvement of gut microbiota in inflammatory bowel diseases (IBD) pathogenesis, in sustaining gut barrier chronic inflammation, and in conditioning disease course and therapeutical response. This evidence provides a rationale for treating patients with gut… Expand
Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice
It is found that rifaximin significantly reduced the severity of AS and resulted in down-regulation of inflammatory factors, such as TNF-α,IL-6, IL-17A, and IL-23, as well as selectively promoting some probiotic populations, including Lactobacillales. Expand
Inflammatory bowel diseases: the role of gut microbiota.
The aim of this review is to summarize both the most recent acquisitions in the field of gut microbiota and its involvement in intestinal inflammation together with the available strategies for the modulation of microbiota, such as prebiotics and/or probiotics administration or fecal microbiota transplantation. Expand
Effects of Rifaximin on Luminal and Wall-Adhered Gut Commensal Microbiota in Mice
Rifaximin, although its antibacterial properties, induces minor changes in luminal and wall-adhered GCM in healthy mice and no modulation of TLRs or local immune systems was observed, which does not rule out a modulatory role in inflammatory and or dysbiotic states of the gut. Expand
Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model
Rifaximin decreased the IgAN symptoms observed in α1KI-CD89Tg mice, suggesting a possible role for it in the treatment of the disease. Expand
Detection of High-Level Rifaximin Resistance in Enteric Bacteria by Agar Screen.
The authors' agar screen test has the potential to detect high-level rifaximin-resistant Enterobacterales, which remain rare among extended spectrum beta-lactamase (ESBL)-positive enteric bacteria, but may emerge among patients receiving rifaxIMin for prevention of hepatic encephalopathy and spontaneous bacterial peritonitis or among patients received rifaxin for other indications. Expand


Rifaximin in the treatment of inflammatory bowel disease.
  • M. Guslandi
  • Medicine
  • World journal of gastroenterology
  • 2011
Rifaximin α polymer is an antibacterial agent that is virtually unabsorbed after oral administration and is devoid of systemic side effects and might also have a role in maintaining remission of ulcerative colitis and pouchitis. Expand
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
Rifaximin has been demonstrated to exert beneficial effects on cognitive function in patients with HE, and also to prevent the development of SBP, to reduce endotoxemia and to improve hemodynamics in cirrhotics, linked to a shift in gut microbes functionality, triggering the production of favorable metabolites. Expand
Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin.
Among antibiotics, Rifaximin seems to be a promising antibiotic to treat conditions related to gut microbiota imbalance and to potentially modulate intestinal homeostasis and detailed mechanistic studies will improve the development of targeted therapies that may shape gut microflora composition with the end goal of promoting gut health. Expand
Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases
  • R. Sartor
  • Medicine
  • Alimentary pharmacology & therapeutics
  • 2016
Rifaximin, traditionally identified as a nonsystemic bactericidal antibiotic, may be therapeutically beneficial for inducing CD remission. Expand
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin
It is suggested that rifaximin can exert important eubiotic effects independently of the original disease, producing a favorable gut microbiota perturbation without changing its overall composition and diversity. Expand
Use of antibiotics in the treatment of Crohn's disease.
Rifaximin, characterized by an excellent safety profile, has provided promising results in inducing remission of CD, and the use of metronidazole and ciprofloxacin is recommended in perianal disease. Expand
Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.
It is demonstrated that rifaximin, while not altering the overall structure of the human colonic microbiota, increased bifidobacteria and led to variation of metabolic profiles associated with potential beneficial effects on the host. Expand
Effect of Rifaximin on Intestinal Bacterial Overgrowth in Crohn's Disease as Assessed by the H2-Glucose Breath Test
Short-term administration of rifaximin is effective in the therapy of bacterial overgrowth in patients with inactive CD of the ileum, thus suggesting that the control of luminal bacterial growth could be useful in the management of these patients. Expand
Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches
The microbial basis for IBDs and the results of the most recent trials of fecal microbial transplant, antibiotics, probiotics, and prebiotics are reviewed and comment on possible safety concerns with these agents, speculate on why they have failed to show efficacy in certain clinical settings, and propose strategies to improve their usefulness. Expand
Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.
Rifaximin alters the bacterial population in the ileum of rats, leading to a relative abundance of Lactobacillus, which prevents intestinal abnormalities and visceral hyperalgesia in response to chronic psychological stress. Expand